Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Jun:139:104838.
doi: 10.1016/j.jcv.2021.104838. Epub 2021 Apr 21.

Evaluation of an antigen-based test for hospital point-of-care diagnosis of SARS-CoV-2 infection

Gabriele Bianco  1 , Matteo Boattini  2 , Anna Maria Barbui  2 , Gitana Scozzari  3 , Franco Riccardini  4 , Maurizio Coggiola  5 , Enrico Lupia  4 , Rossana Cavallo  2 , Cristina Costa  2
Affiliations
Observational Study

Evaluation of an antigen-based test for hospital point-of-care diagnosis of SARS-CoV-2 infection

Gabriele Bianco et al. J Clin Virol. 2021 Jun.

Abstract

Background: An accurate diagnosis is essential to identify and manage SARS-CoV-2 infected patients and implement infection control measures. Although real-time reverse transcription polymerase chain reaction (RT-PCR) is the current recommended laboratory method, several rapid antigen point-of-care tests (POCTs) were developed as frontline testing for SARS-CoV-2 infection diagnosis.

Objectives: The aim of this study was to assess a recently CE-approved POCT, SARS-CoV-2 Ag Test on the LumiraDx™ Platform (LumiraDx GmbH, Cologne, Germany) for the identification of SARS-COV-2 infected subjects at hospital setting.

Methods: LumiraDx POCT was implemented in three hospital settings: adult and pediatric emergency departments and occupational medicine department along two-month period during the second peak of Italian SARS-CoV-2 pandemic. Rapid antigen testing was performed on direct nasal swabs and results were compared with those obtained by Xpert Xpress SARS-CoV-2 assay.

Results: Overall sensitivity, specificity, NPV and PPV were 90.3%, 92.1%, 95.1%, and 84.9%, respectively, compared to reference method. Sensitivity, specificity, PPV and NPV for symptomatic group were 89.3% [95% IC 84.2-93.3], 88.2% [95% IC 72.5-96.7], 97.8% [95% IC 94.6-99.1], and 58.8% [95% IC 48.4-68.5], respectively. Sensitivity, specificity, PPV and NPV for asymptomatic group were 92.1% [95% IC 85-96.5], 92.3% [95% IC 89.9-94.4], 67.9% [95% IC 61.3-73.8], and 98.5% [95% IC 97.1-99.2], respectively. False positive and negative antigen testing results in both symptomatic and asymptomatic group were observed.

Conclusion: SARS-CoV-2 Ag POCT may represent an interesting tool to rapidly identify symptomatic or asymptomatic infected subjects. However, in hospital setting in which false negative or false positive results may have relevant implications, confirmatory NAAT always remains necessary for the appropriate management of patients.

Keywords: Antigen test; Healthcare workers; Hospital screening; Point-of-care-testing; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Wu F., Zhao S., Yu B., Chen Y.-.M., Wang W., Song Z.-.G. A new coronavirus associated with human respiratory disease in China. Nature. 2020:1–8. doi: 10.1038/s41586-020-2008-3. - DOI - PMC - PubMed
    1. WHO . 2020. Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020.https://www.who.int/dg/speeches/detail/who-director-general-s-opening-re... 19—11-march-2020.
    1. WHO WHO . Interin Guidance; 2020. Laboratory testing for coronavirus disease (COVID-19) in suspected human cases.
    1. CDC C-NC-nR-TR-PDP CDC . 2020. CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel.
    1. Porte L., Legarraga P., Vollrath V., Aguilera X., Munita J.M., Araos R., et al. Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples. Int. J. Infect. Dis. 2020;99:328–333. doi: 10.1016/j.ijid.2020.05.098. - DOI - PMC - PubMed

Publication types

Substances